Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase

BACKGROUND: Pegloticase is a recombinant mammalian uricase conjugated to polyethylene glycol approved in the United States for treatment of chronic refractory gout. It can profoundly decrease serum urate to < 1 mg/dl. In patients receiving pegloticase who did not generate high-titer antidrug anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Mandell, Brian F., Yeo, Anthony E., Lipsky, Peter E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311031/
https://www.ncbi.nlm.nih.gov/pubmed/30594229
http://dx.doi.org/10.1186/s13075-018-1782-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311031/
https://www.ncbi.nlm.nih.gov/pubmed/30594229
http://dx.doi.org/10.1186/s13075-018-1782-x

Ejemplares similares